Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (NCT05021536)

🧪 Interventions in This Study

• AMX0035 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (69 Sites)

Showing the first 25 of 69 sites.

• Barrow Neurological Institute — Phoenix, Arizona
• University of Southern California — Los Angeles, California
• University of California Irvine — Orange, California
• California Pacific Medical Center Research Institute — San Francisco, California
• University of Colorado — Aurora, Colorado
• University of Florida — Gainesville, Florida
• University of South Florida — Tampa, Florida
• Emory University — Atlanta, Georgia
• Augusta University Neuroscience Center — Augusta, Georgia
• Northwestern University — Chicago, Illinois
• Johns Hopkins University School of Medicine Outpatient Center — Baltimore, Maryland
• Healey & AMG Center for ALS Research at Massachusetts General Hospital — Boston, Massachusetts
• University of Massachusetts — Worcester, Massachusetts
• Hennepin Healthcare Research Institute — Minneapolis, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Somnos Clinical Research — Lincoln, Nebraska
• Rutgers University — New Brunswick, New Jersey
• Columbia University — New York, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Wake Forest University Health Sciences — Winston-Salem, North Carolina
• The Ohio State University — Columbus, Ohio
• University of Pennsylvania — Philadelphia, Pennsylvania
• Lewis Katz School of Medicine at Temple University — Philadelphia, Pennsylvania
• Austin Neuromuscular Center — Austin, Texas
• Texas Neurology — Dallas, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Amyotrophic Lateral Sclerosis

• Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) — Toronto, Ontario
• Regulatory T Cells for Amyotrophic Lateral Sclerosis — New York, New York
• Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) — Phoenix, Arizona
• TRIAL READY (Clinical Trial Readiness) — Miami, Florida
• Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS — New York, New York

Explore by condition: All Amyotrophic Lateral Sclerosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.